Will T-cell therapy for cancer ever be a standard of care?

M. K. Brenner

doi:10.1038/cgt.2012.74

Will T-cell therapy for cancer ever be a standard of care?

M. K. Brenner

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Cellular therapies for cancer are showing increasing efficacy but their introduction as a 'standard of care' for these disorders is hampered by technical, regulatory and financial concerns. This review identifies some of the major problems and suggests potential solutions.

Original language	English (US)
Pages (from-to)	818-821
Number of pages	4
Journal	Cancer Gene Therapy
Volume	19
Issue number	12
DOIs	https://doi.org/10.1038/cgt.2012.74
State	Published - Dec 2012

Keywords

cancer
commercialization
T-cell therapy

ASJC Scopus subject areas

Cancer Research
Molecular Medicine
Molecular Biology

Access to Document

10.1038/cgt.2012.74

Cite this

@article{db61348f37e447ccb2d434b89789cb07,

title = "Will T-cell therapy for cancer ever be a standard of care?",

abstract = "Cellular therapies for cancer are showing increasing efficacy but their introduction as a 'standard of care' for these disorders is hampered by technical, regulatory and financial concerns. This review identifies some of the major problems and suggests potential solutions.",

keywords = "cancer, commercialization, T-cell therapy",

author = "Brenner, \{M. K.\}",

year = "2012",

month = dec,

doi = "10.1038/cgt.2012.74",

language = "English (US)",

volume = "19",

pages = "818--821",

journal = "Cancer Gene Therapy",

issn = "0929-1903",